[The study of relationship between platelet function and thrombus in patients with essential thrombocythaemia].
OBJECTIVE
To observe the influence of the plasma thromboxane B2 (TXB2), 6-keto-PGF1alpha, CD62P and PAC-1 and Thrombus in patients with primary thrombocytosis (ET). To observe the effect of sodium ozagrel to prevent and treat thrombosis in patients with ET.


METHODS
The subjects including 48 patients with ET. All patients were measured the plasma TXB2, 6-keto-PGF1alpha, CD62P and PAC-1 before and after treatment with or without sodium ozagrel.


RESULTS
The plasma levels of CD62P, PAC-1, TXB2, 6-keto-PGF1alpha and TXA2/PGI2 in the patients with ET were significantly higher than the normal people (P < 0.01). The levels of CD62P, PAC-1, TXB2, TXB2/6-keto-PGF1alpha in patients with treatment of sodium ozagrel were higher than patients without treatment of sodium ozagrel (P < 0.01). The plasma levels of CD62P, PAC-1 and TXA2/PGI2 in patients with treatment of sodium ozagrel and that in normal people had no significant distinction (P < 0.01). All the index of conventional therapy group were higher than normal people (P < 0.01) but had no significant distinction with the patients before conventional treating. The incidence of thrombus in patients treated with sodium ozagrel was lower than patients treated without sodium ozagrel (P < 0.05).


CONCLUSIONS
With the treatment of sodium ozagrel in patients with ET, the CD62P, PAC-1, TXB2 and TXA2/PGI2 of plasma could be decreased. And the incidence of thrombus was decreased.
Yao
Hong-Xia
HX
Department Hematology of Hainan Provincial People's Hospital, Haikou 570311, China. Email: yaohongxia768@gmail.com.
Huang
Li
L
Lin
Li-E
LE
Wu
Cong-Ming
CM
Wang
Hua
H
Chen
Wen-Ting
WT
Fu
Xiang-Jun
XJ
Ding
Yi-Peng
YP
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000328:Adult; D000911:Antibodies, Monoclonal / Q000097:blood*; D001792:Blood Platelets / Q000502:physiology*; D005260:Female; D006801:Humans; D008297:Male; D008689:Methacrylates / Q000627:therapeutic use*; D008875:Middle Aged; D019007:P-Selectin / Q000097:blood; D039341:Receptors, Fibrinogen / Q000276:immunology; D051237:Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I / Q000097:blood; D013920:Thrombocythemia, Essential / Q000503:physiopathology*; D013927:Thrombosis / Q000188:drug therapy / Q000517:prevention & control*; D013928:Thromboxane A2 / Q000097:blood; D013929:Thromboxane B2 / Q000097:blood
D000911:Antibodies, Monoclonal; D008689:Methacrylates; D019007:P-Selectin; D039341:Receptors, Fibrinogen; D051237:Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I; D013929:Thromboxane B2; D013928:Thromboxane A2; D015121:6-Ketoprostaglandin F1 alpha; C034364:ozagrel